FFT-NEURO: A Novel Multi-Biomarker Platform for Early Detection of Alzheimer's Disease in Underserved Communities

Abstract Alzheimer’s disease (AD) remains one of the most devastating and costly neurodegenerative conditions, particularly in underserved communities where access to early diagnostics is limited. Omni Care Oasis L.L.C. has developed FFT-NEURO, a non-invasive, AI-powered diagnostic platform that integrates a 5-biomarker blood panel—Aβ42, total tau, phosphorylated tau, neurofilament light chain (NfL), and heme oxygenase-1 (HO-1)—to detect Alzheimer’s pathology 6–12 months before clinical symptom onset. Leveraging ELISA and qRT-PCR for sample analysis and powered by the BioGuard AI engine, FFT-NEURO aims to achieve ≥90% sensitivity and specificity, with projected AUC values between 0.90 and 0.95 based on peer-reviewed benchmarks.